Read Original Story

Cutting edge nail cure


0 Star

Cutting edge nail cure

Our Review Summary

Everytime you think you’ve seen the worst use of network TV time on "health" topics, something lower pops up on the screen.

Such was the case with ABC’s promotion of an off-label unapproved use of a laser for toenail fungus.  

The ad – er, story – told us: 

• "About half of all Americans over the age of 50 are struggling with this problem." Struggling? Really? Enough to warrant a $1200 treatment ($120 per toe) that is NOT covered by insurance? This is part of the 16% of the GDP that Americans spend on health care.

• ABC profiled one woman: "Meghan, like millions of Americans, has had her toe fungus for 15 years. It’s unsightly, embarrassing. And like others, she suffered in silence, not wanting to talk about it." Millions of us like poor Meghan – suffering in silence? But not silent any longer – thanks to almost 5 minutes of network news time.

• It’s just been introduced, but it’s already used by many podiatrists, but more testing is needed.  But the story didn’t give any warnings about such proliferation of non-FDA approved uses of technologies.  

ABC said this was "news for tens of millions of you out there right now."  So is the fact that we spend 16% of the GDP on health care – much of it on stuff like this.  

If you’re going to do a story on this topic – and it’s hard to avoid given how much Americans spend on it – check out the recent New York Times story for comparison.  ABC’s segment wasn’t even in the ballpark.  


Does the story adequately discuss the costs of the intervention?

Not Satisfactory

Costs were covered – $120 per toe – not covered by insurance. But we are suspicious of the claimed 88% success rate and the number of treatments required to attain the level of "success" portrayed in the story. This may not be a one-shot, $1,200 deal.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

No discussion of any harms.  Everything carries a potential harm.  What do the studies show?

Does the story seem to grasp the quality of the evidence?

Not Satisfactory

We’re told that the laser maker says it’s 88% effective.  What does that mean?  88% never have a problem again?  88% get one treatment and that’s it?  What happens to the other 12%?  The network gave almost 5 minutes of airtime to this; they could have given more meaningful evidence.  "Success" is not necessarily the same as the proclaimed "cure."

Does the story commit disease-mongering?

Not Satisfactory

Classic case of disease mongering.  Millions of us have it?  Suffering in silence?  Gag me.

Does the story use independent sources and identify conflicts of interest?

Not Satisfactory

Two true-believer health care professionals were profiled.  No independent source appeared.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

The story mentions topical solutions with limited effectiveness.  And a prescription drug whose "side effects need to be closely monitored with blood tests."  But no such scrutiny was applied to the off-label laser idea.  That’s an unlevel playing field. Not news – but advertising promotion via network TV.

Does the story establish the availability of the treatment/test/product/procedure?

Not Satisfactory

We’re told that many podiatrists are already using the laser for toenail fungus.  But that doesn’t tell us much.  We’re also told it was just introduced at the American Academy of Dermatology meeting.  So which is it:  just introduced?  Or many already using it? Only 13 clinicians are listed on the company’s website as providers.

Does the story establish the true novelty of the approach?

Not Satisfactory

Is it an ethical use of network news time to give 5 minutes to something that is being promoted for off-label use? Do viewers really understand what that means?  The novelty may come at a cost – and the network fawningly went along with all of the claims. 

Toenail fungus is big business and as a result a number of approaches have been used and many are still in development.  While one company’s laser was highlighted others are testing similar devices.  In addition, other drugs and approaches are in the developmental stages as well.  The promotion of an off label use that has no published study results available raises significant issues. 

Does the story appear to rely solely or largely on a news release?

Not Applicable

We can’t be sure if the story relied soley or largely on a news release. 

Total Score: 0 of 9 Satisfactory


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.